Advertisement
Canada markets close in 1 hour 40 minutes

  • S&P/TSX

    21,972.87
    +87.49 (+0.40%)
     

  • S&P 500

    5,105.03
    +56.61 (+1.12%)
     

  • DOW

    38,281.60
    +195.80 (+0.51%)
     

  • CAD/USD

    0.7320
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    83.91
    +0.34 (+0.41%)
     

  • Bitcoin CAD

    87,401.23
    -1,026.80 (-1.16%)
     

  • CMC Crypto 200

    1,332.83
    -63.70 (-4.56%)
     

  • GOLD FUTURES

    2,350.70
    +8.20 (+0.35%)
     

  • RUSSELL 2000

    2,003.63
    +22.51 (+1.14%)
     

  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     

  • NASDAQ

    15,928.04
    +316.28 (+2.03%)
     

  • VOLATILITY

    15.10
    -0.27 (-1.76%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Risankizumab Could Be AbbVie’s Long-Term Growth Driver

Daniel Collins
Updated
Risankizumab Could Be AbbVie’s Long-Term Growth Driver

In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.

Continue reading